Latest news with #TevaPharmaceuticals
Yahoo
21-07-2025
- Business
- Yahoo
Viatris' blepharitis ointment fails Phase III trial
Viatris' investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug's future. The Phase III study (NCT06400511) evaluated the efficacy and safety of MR-139 (pimecrolimus 0.3%) ophthalmic ointment in 477 patients with the condition. Blepharitis usually affects both eyes along the edges of the eyelids and results from clogged oil glands at the base of the eyelashes. The study failed to reach the primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. After the failure was announced, Viatris' stock dropped 4.2%, from $9.27 at market close on 17 July to $8.88 at market close on 18 July. The US company has a market cap of $10.42bn. Viatris' chief R&D officer Philippe Martin said the company is currently working out the next steps for MR-139 in blepharitis. Martin said: "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase III programme, which may include revising the planned additional Phase III study.' A cream formulation of pimecrolimus, marketed as Eildel, was approved in 2001 for use in a number of dermatology indications by Novartis. Generics have since been approved by companies, including Teva Pharmaceuticals and Glenmark Therapeutics. The therapy has not been approved in any ophthalmology indications. Last month, the company's phentolamine ophthalmic solution 0.75% was successful in a second Phase III presbyopia study, with the company eyeing FDA approval of the therapy. In the same month, Viatris also had success in the Phase III LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Approved treatments for blepharitis include steroid eyedrops and topical antibiotics; however, in some circumstances, oral antibiotics may also be prescribed. For Demodex blepharitis, Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution) is prescribed to target and eliminate the mites on the eyelashes responsible for the condition. GlobalData predicts Xdemvy to reach blockbuster status in 2030, with a global sales forecast of $1.03bn. GlobalData is the parent company of Clinical Trials Arena. "Viatris' blepharitis ointment fails Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
09-07-2025
- Business
- Yahoo
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is an investigational anti-PD1-IL2 ATTENUKINE therapy. The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
01-07-2025
- Business
- Yahoo
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For example, the Teva Pharmaceutical Industries Limited (NYSE:TEVA) share price has soared 112% in the last three years. Most would be happy with that. In the last week shares have slid back 1.2%. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Teva Pharmaceutical Industries wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. Over the last three years Teva Pharmaceutical Industries has grown its revenue at 3.6% annually. Considering the company is losing money, we think that rate of revenue growth is uninspiring. In contrast, the stock has popped 29% per year in that time - an impressive result. Shareholders should be pretty happy with that, although interested investors might want to examine the financial data more closely to see if the gains are really justified. It may be that the market is pretty optimistic about Teva Pharmaceutical Industries if you look to the bottom line. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). Teva Pharmaceutical Industries is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. You can see what analysts are predicting for Teva Pharmaceutical Industries in this interactive graph of future profit estimates. Teva Pharmaceutical Industries shareholders are up 2.6% for the year. Unfortunately this falls short of the market return. On the bright side, the longer term returns (running at about 8% a year, over half a decade) look better. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. You could get a better understanding of Teva Pharmaceutical Industries' growth by checking out this more detailed historical graph of earnings, revenue and cash flow. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Miami Herald
29-06-2025
- Health
- Miami Herald
An acid reflux drug got recalled. Company says bottles might have different meds
One lot of reflux medicine got recalled when fluid retention tablets were discovered in the medicine bottles. Teva Pharmaceuticals pulled lot No. 5420094 of 10 mg Metoclopramide tablets in 100-count bottles after 'a single 20 mg Torsemide tablet that does not belong was discovered in each of three individual sealed bottles of 10 mg Metoclopramide tablets.' It comes from the Teva press release posted to the company website that the FDA apparently missed when it stated 'press release not issued for this recall' under the press release URL part of the FDA's enforcement alert. Metoclopramide treats reflux symptoms in adults after failure of normal treatments. 'Torsemide is used to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, kidney disease,' the Mayo Clinic said. READ MORE: Broward drug company recalls 3 eye drugs that might not be sterile The FDA classified this as a Class II recall, meaning problems caused by this mixup shouldn't last long, and there's a 'remote' chance of serious problems. '...the likelihood of an unintended drug reaction occurrence is remote/unlikely as Metoclopramide tablets will not be dispensed in the original packaging but will be divided at the pharmacy level,' Teva said. 'and be dispensed in smaller quantities for patient use, where the difference in tablets is likely to be noticed by the pharmacist.' 'Likely' although there's not much difference in how each medication looks. Teva says the 10 mg Metoclopramide tablets are white, round, dividing line on one side, '2203' above the divider on that side and 'TEVA' on the other side. The National Library of Medicine describes the 20 mg Torsemide tablets are white, round, dividing line on one side with '917' above the divider. The Metoclopramide tablets are 8 millimeters in size, while the Torsemide tablets are 10 millimeters. For instructions on how to return the recalled lot, which has an expiration date of 9/2027, go to Teva's online consumer recall letter. Direct questions about this recall to 888-838-2872, option 4, Monday through Friday, 9 a.m. to 5 p.m., Eastern time to speak to a person. Voice mail works 24 hours a day. If you have a medical problem because you think a wayward Torsemide tablet was taken by a Metoclopramide user, call a medical professional. Then, notify the FDA MedWatch adverse event program. Third, call Teva at 888-838-2872, option 3, then option 4, Monday through Friday, 9 a.m. to 5 p.m., Eastern time, or email USMedInfo@
Yahoo
24-06-2025
- Business
- Yahoo
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Goldman Sachs analysts began coverage of Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $24, on June 6. The analysts' optimistic view was driven in part by a strengthening core business and growth possibilities in the branded segment. According to the analysts, Teva's branded segment, which includes medications like Austedo, Uzedy, Ajovy, and LAI olanzapine, has significant growth potential. They estimate that these assets will generate substantial growth in fiscal year 2027, around 10% higher than the mainstream projections. This optimism stems from recent script data and commercial investments, including direct-to-consumer marketing. On the other hand, Goldman Sachs analysts see modest growth in the generics sector over the upcoming years. Although Teva's growing portfolio of biosimilars—five more are anticipated to be introduced in the United States between fiscal years 2025 and 2027—offers potential, the gRevlimid settlement's expiration in 2026 may offset this growth. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a multinational pharmaceutical company based in Israel. Although generic medications are Teva's primary area of expertise, the company also has branded drug assets. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
